As the depth and breadth of BioCT’s mission expands, our work at the state capitol and in Washington, D.C. continues unabated. Government policy and advocacy is a critical component of our community outreach. We have convened a government affairs committee comprising BioCT board members and business and advisory delegates, including the government relations firm of Rome, Smith & Lutz, which has expertise in matters impacting our sector, to inform our policy and advocacy strategies.
The mission of the committee is to provide education and advocacy for Connecticut’s bioscience and life science communities at the government policy level, and to ensure synergy of action and alignment of state and federal initiatives. The committee will inform public policy decision-making that has a significant impact on our membership.
We strive to work proactively to articulate the development of Connecticut’s bioscience sector and will continue to monitor and weigh in, where necessary, on bills related to research and development and laboratory practices that have impact on our membership and life sciences research.
BioCT has been instrumental in state budget allocations for research funding, successfully securing such investments in the face of fiercely competing priorities. In a fast-paced industry we also have an important role to play in keeping policy makers abreast of the latest developments and changing needs affecting the life sciences in Connecticut.
BioCT’s advocacy wins at the state level include:
• A $100 million-10-year stem cell research program, the first of its kind
• 6% tax credit for continuing research and development
• 20% tax credit for new research and development
• 65-cents-on-the-dollar refundable R&D tax credit
• Biopharma sales and use tax exemption
• 20 year net operating loss carry-forward period
• Bioscience Innovation Act, a $200 million fund for start-ups and entrepreneurs
• $1.5 billion Next Generation Connecticut legislation for strengthening STEM education
Federal advocacy focuses on the continuing robustness of these agencies:
• Food and Drug Administration (FDA)
• National Institutes of Health (NIH)
• National Center for Advancing Translational Sciences (NCATS)
• Career Acceleration Network (CAN)
• US Patent Office (USPTO)
BioCT is represented by Rome Smith & Lutz and partner Katherine Lutz on CT state legislative affairs. She can be reached at email@example.com.
Briefs, Letters & Issues of Interest
The full membership of the Federal Circuit will not rehear a three-judge panel’s ruling that Sequenom’s methods for detecting paternity DNA in a prenatal sample are ineligible for patenting….
Earlier this summer, in Ariosa Diagnostics, Inc. v. Sequenom, Inc., the Federal Circuit affirmed a decision by the District Court for the Northern District of California…
The following letter was sent to Representatives John Larson, Elizabeth Esty, Jim Himes, Joe Courtney, and Rosa DeLauro:
The following letter was sent to Senators Richard Blumenthal and Christopher Murphy; Representatives Elizabeth Esty, Jim Himes, Joe Courtney, and Rosa DeLauro: